Hidradenitis Suppurativa Prevalence in Nuuk, Greenland: Physician Validation of a Hidradenitis Suppurativa Questionnaire in a Greenlandic Setting
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Forlagets udgivne version, 598 KB, PDF-dokument
|Status||Udgivet - 2023|
The study was supported by the Greenlandic Research Foundation for Medical Doctors in Greenland. We would especially like to thank our Greenlandic colleagues Aviannguaq Kreutzmann and Trine Pedersen Abelsen for their indispensable contribution to this study. This study could not have been conducted without their translations and knowledge of the Greenlandic Inuit language. We would also like to thank all the patients, who let us examine them and take clinical photographs of their skin conditions. Conflicts of interest: DB: UCB Nordic has paid for EADV congress participation. RKA: Eli Lilly has paid for NCDV 2022 congress participation. SFT has been a speaker or advisor for Sanofi, AbbVie, LEO Pharma, Pfizer, Eli Lilly, Novartis, UCB Pharma, Almirall, Union Therapeutics, and Janssen Pharmaceuticals; and has received research support from Sanofi, AbbVie, LEO Pharma, Novartis, UCB Pharma, and Janssen Pharmaceuticals, outside the submitted work. DMS received honoraria as a consultant for advisory board meetings by AbbVie, Janssen, Sanofi, LeoPharma and as a speaker and/or received grants from the following companies: Abbvie, Janssen, Novartis, Sanofi and Leo Pharma during the last 3 years. GBEJ has received research funding and/or honoraria from Abbvie, InflRx, Janssen-Cilag, Leo Pharma, Novartis, ChemoCentryx, Regeneron and Serono. The other authors have no conflicts of interest to declare.